These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24163168)

  • 1. [Vasopressin receptor antagonists in therapy of congestive heart failure].
    Gassanov N; Taghiyev Z; Le MT; Biesenbach E; Baldus S; Er F
    Dtsch Med Wochenschr; 2013 Nov; 138(45):2313-8. PubMed ID: 24163168
    [No Abstract]   [Full Text] [Related]  

  • 2. Digitalis for treatment of congestive heart failure in patients in sinus rhythm.
    Cayley WE
    Am Fam Physician; 2004 Jan; 69(1):71-2. PubMed ID: 14727819
    [No Abstract]   [Full Text] [Related]  

  • 3. The challenge of treating congestion in advanced heart failure.
    Bonios MJ; Terrovitis JV; Kaldara E; Ntalianis A; Nanas JN
    Expert Rev Cardiovasc Ther; 2011 Sep; 9(9):1181-91. PubMed ID: 21932961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New pharmacologic therapies for acute heart failure.
    Tavares M; Rezlan E; Vostroknoutova I; Khouadja H; Mebazaa A
    Crit Care Med; 2008 Jan; 36(1 Suppl):S112-20. PubMed ID: 18158470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prospects of arginine vasopressin receptor antagonists in the treatment for heart failure].
    Liu YM; Zhu ZM; Yang Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jul; 35(7):678-80. PubMed ID: 17961443
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure].
    Tamargo J; López-Sendón J
    Rev Esp Cardiol; 2004 May; 57(5):447-64. PubMed ID: 15151778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin antagonists in the management of heart failure.
    Rossi J; Orlandi C; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):323-30. PubMed ID: 17338675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of heart failure in the elderly].
    Zobel C; Schwinger RH
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():47-50. PubMed ID: 16802519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of heart failure: a brief review and selected update.
    Unzek S; Francis GS
    Cardiol Clin; 2008 Nov; 26(4):561-71. PubMed ID: 18929231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg A
    Am J Kidney Dis; 2007 Dec; 50(6):904-7. PubMed ID: 18037090
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging therapies for the management of decompensated heart failure: from bench to bedside.
    deGoma EM; Vagelos RH; Fowler MB; Ashley EA
    J Am Coll Cardiol; 2006 Dec; 48(12):2397-409. PubMed ID: 17174176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
    Streefkerk JO; van Zwieten PA
    Auton Autacoid Pharmacol; 2006 Apr; 26(2):141-8. PubMed ID: 16553642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopressin antagonism: a future treatment option in heart failure.
    Sanghi P; Uretsky BF; Schwarz ER
    Eur Heart J; 2005 Mar; 26(6):538-43. PubMed ID: 15695526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
    Pang PS; Gheorghiade M; Dihu J; Swedberg K; Khan S; Maggioni AP; Grinfeld L; Zannad F; Burnett JC; Ouyang J; Udelson JE; Konstam MA
    Am Heart J; 2011 Jun; 161(6):1067-72. PubMed ID: 21641352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?
    Filippatos G; Parissis JT
    J Card Fail; 2008 Oct; 14(8):648-50. PubMed ID: 18926435
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diuretic use in heart failure and outcomes.
    von Lueder TG; Atar D; Krum H
    Clin Pharmacol Ther; 2013 Oct; 94(4):490-8. PubMed ID: 23852396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Congest Heart Fail; 2010 Jul; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER; Sanghi P
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.